Cancer research

Overcoming glioblastoma resistance to temozolomide by blocking energy production and DNA repair

Updated

Abstract

The combination of BER and NAD(+) biosynthesis inhibition significantly sensitizes glioma cells with elevated MGMT expression and MMR deficiencies.

  • Glioblastoma multiforme (GBM) has a poor prognosis and low median survival time.
  • Resistance to the chemotherapy drug temozolomide (TMZ) is common due to high levels of the repair protein MGMT or defects in the mismatch repair pathway.
  • Inhibition of base excision repair (BER) can enhance the response to TMZ in resistant glioma cells.
  • Blocking BER leads to the accumulation of DNA repair intermediates that cause cell death through energy depletion.
  • The efficacy of TMZ may be increased by simultaneously inhibiting BER and the biosynthesis of nicotinamide adenine dinucleotide (NAD(+)).
  • Targeting both DNA repair and NAD(+) biosynthesis pathways could be an effective strategy for treating resistant and recurrent GBM.

Simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free